Revelation Biosciences Warrant
REVBW
11 hedge funds and large institutions have $6.66K invested in Revelation Biosciences Warrant in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.
38% more capital inflows, than outflows
Capital inflows: $11 | Capital outflows: $8
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5 |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3 |
| 3 |
Clear Street
New York
|
+$2 |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIS
POM Investment Strategies
Raleigh,
North Carolina
|
-$8 |
REVBW Hedge Fund Activity: Q1 2026 in Review
11 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences Warrant (REVBW) for Q1 2026, worth a combined $6.66K — down 35% from $10.2K a quarter earlier.
Fund positioning in REVBW was balanced in Q1 2026: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $5. The largest seller was POM Investment Strategies, exiting entirely with an estimated $8 sold.
- 11 institutional investors held Revelation Biosciences Warrant (REVBW) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $6.66K of Revelation Biosciences Warrant stock for Q1 2026, down 35% quarter-over-quarter.
- 1 fund opened new Revelation Biosciences Warrant positions in Q1 2026 and 1 closed out, a net change of 0 holders.
- The largest Revelation Biosciences Warrant buyer in Q1 2026 was UBS Group, an estimated $5 added.
- The largest Revelation Biosciences Warrant seller in Q1 2026 was POM Investment Strategies, an estimated $8 sold.
Based on aggregated 13F filings for Q1 2026.